Pharmacological activity
ChemicalBook > CAS DataBase List > 2-ButynaMide, N-[4-[(3-broMophenyl)aMino]-6-quinazolinyl]-

2-ButynaMide, N-[4-[(3-broMophenyl)aMino]-6-quinazolinyl]-

Pharmacological activity
Product Name
2-ButynaMide, N-[4-[(3-broMophenyl)aMino]-6-quinazolinyl]-
CAS No.
194423-06-8
Chemical Name
2-ButynaMide, N-[4-[(3-broMophenyl)aMino]-6-quinazolinyl]-
Synonyms
785;CL-387;CS-1630;EKB 785;-387785;CL-38875;WAY-EKI 785;CL-387785, >=98%;EKI-785 CL-38875;CL-387785 (EKI-785)
CBNumber
CB92626313
Molecular Formula
C18H13BrN4O
Formula Weight
381.23
MOL File
194423-06-8.mol
More
Less

2-ButynaMide, N-[4-[(3-broMophenyl)aMino]-6-quinazolinyl]- Property

Melting point:
276 °C
Density 
1.577±0.06 g/cm3(Predicted)
storage temp. 
Sealed in dry,Store in freezer, under -20°C
solubility 
insoluble in EtOH; insoluble in H2O; ≥16.85 mg/mL in DMSO
pka
9.84±0.43(Predicted)
form 
Off-white to yellow solid.
color 
White to Orange to Green
More
Less

Safety

HS Code 
2933.59.5300
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
233100
Product name
CL-387,785 - CAS 194423-06-8 - Calbiochem
Packaging
1MG
Price
$150
Updated
2025/07/31
TCI Chemical
Product number
C3575
Product name
CL-387785
Packaging
25MG
Price
$150
Updated
2025/07/31
TCI Chemical
Product number
C3575
Product name
CL-387785
Packaging
100MG
Price
$410
Updated
2025/07/31
Cayman Chemical
Product number
19081
Product name
CL-387785
Purity
≥95%
Packaging
1mg
Price
$37
Updated
2024/03/01
Cayman Chemical
Product number
19081
Product name
CL-387785
Purity
≥95%
Packaging
5mg
Price
$116
Updated
2024/03/01
More
Less

2-ButynaMide, N-[4-[(3-broMophenyl)aMino]-6-quinazolinyl]- Chemical Properties,Usage,Production

Pharmacological activity

Overactivity of epidermal growth factor receptor (EGFR) tyrosine kinase activity has been associated with a number of cancers.CL 387,785 profoundly blocks the growth of EGFR-overexpressing tumors in nude mice when given orally at 80 mg/kg/day for 10 days.

Description

Overactivity of epidermal growth factor receptor (EGFR) tyrosine kinase activity has been associated with a number of cancers. CL 387,785 is a potent, irreversible inhibitor of EGFR kinase activity (IC50 = 370 pM). It blocks EGF-stimulated autophosphorylation of receptors in cells (IC50 = 5 nM) and halts cell cycling in cells that overexpress EGFR or c-ErbB2 (IC50s = 31-125 nM). CL 387,785 profoundly blocks the growth of EGFR-overexpressing tumors in nude mice when given orally at 80 mg/kg/day for 10 days.

Uses

CL-387785 (EKI-785) is an irreversible and selective EGFR inhibitor showing activity against mutations of the receptor. Potential therapeutic against various type of cancer, including lung cancer.

Definition

ChEBI: A member of the class of quinazolines that is 4,6-diaminoquinazoine in which the one of the hydrogens attached to the amino group at position 4 has been replaced by a m-bromophenyl group while one of the hydrogens attached to the amino group a position 6 has been replaced by a but-2-ynoyl group.

Synthesis

590-93-2

169205-78-1

194423-06-8

General procedure for the synthesis of N-(4-((3-bromophenyl)amino)quinazolin-6-yl)but-2-ynamide from 2-butynoic acid and N4-(3-bromophenyl)quinazoline-4,6-diamine: 2-butynoic acid (196 mg, 2.3 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (385 mg, 2.0 mmol ) were dissolved in DMF (5 mL) and stirred at 25 °C for 20 min. Subsequently 6-amino-4-[(3-bromophenyl)amino]quinazoline (316 mg, 1.0 mmol) was added. The reaction mixture was stirred under nitrogen protection at 25 °C for 14 hours. After that, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (206 mg, 1.0 mmol) and 2-butynoic acid (82 mg, 1.0 mmol) were added again and stirring was continued for 8 hours. Next, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (197 mg, 1.0 mmol) and 2-butynoic acid (93 mg, 1.0 mmol) were added for the third time and stirred for another 12 h at 25 °C. After completion of the reaction, the reaction was quenched with water. The resulting yellow precipitate was collected, sonicated with acetone and treated with triethylamine. Finally, it was purified by preparative thin layer chromatography on silica gel using 1:1 EtOAc/acetone as eluent. The target product was isolated as a yellow solid (20 mg, 4.7% yield) with a melting point of 281-283 °C. 1H NMR [(CD3)2SO]: δ 10.97 (brs, 1H, NH), 9.93 (s, 1H, NH), 8.76 (s, 1H, H5), 8.57 (s, 1H, H2), 8.14 (s, 1H, H2'). 7.84-7.76 (m, 3H, H7, H8, H4'), 7.34 (t, J = 8.1 Hz, 1H, H5'), 7.29 (d, J = 7.8 Hz, 1H, H6'), 2.09 (s, 3H, CH3). Mass spectrum (APCI): 383 (100, 81BrMH+), 382 (23, 81BrM+), 381 (95, 79BrMH+). Calculated values for elemental analysis (C18H13N4BrO-0.3HCl-0.6C3H6O): C, 55.69; H, 3.99; N, 13.12%. Measured values: C, 55.67; H, 3.96; N, 12.93%.

in vitro

cl-387785 covalently bound to egfr. it also specifically inhibited kinase activity of the protein, blocked egf-stimulated autophosphorylation of the receptor in cells, inhibited cell proliferation primarily in a cytostatic manner in cell lines that overexpress egf-r or c-erbb-2 [1].

in vivo

the effects of cl-387785 on tumor growth were assessed in human tumor xenografts implanted s.c. in the flanks of nude mice. cl-387785 inhibited the growth of tumors derived from a431 cells when the drug was administered i.p. or p.o.. inhibitory effects were observed within 7 days after the onset of therapy. no efficacy was observed with cl-387785 in tumors derived from cell lines that did not overexpress egf-r, including the human breast carcinoma mda-mb-435 [1].

IC 50

370 pm

References

[1] discafani cm, carroll ml, floyd mb jr, hollander ij, husain z, johnson bd, kitchen d, may mk, malo ms, minnick aa jr, nilakantan r, shen r, wang yf, wissner a, greenberger lm. irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by n-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (cl-387,785). biochem pharmacol. 1999 apr 15;57(8):917-25.

2-ButynaMide, N-[4-[(3-broMophenyl)aMino]-6-quinazolinyl]- Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

2-ButynaMide, N-[4-[(3-broMophenyl)aMino]-6-quinazolinyl]- Suppliers

Shanghai Boyle Chemical Co., Ltd.
Tel
Fax
86-21-57758967
Email
sales@boylechem.com
Country
China
ProdList
2922
Advantage
55
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
sales@meilune.com
Country
China
ProdList
4747
Advantage
58
Jiangsu Aikon Biopharmaceutical R&D co.,Ltd.
Tel
025-66113011 17798518460
Fax
(1)02557626880
Email
cfzhang@aikonchem.com
Country
China
ProdList
19913
Advantage
55
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Fax
(86) 21-58955996
Email
info@chemexpress.com
Country
China
ProdList
7552
Advantage
61
TOKYO CHEMICAL INDUSTRY CO., LTD.
Tel
03-36680489
Fax
03-3668-0520
Email
Sales-JP@TCIchemicals.com
Country
Japan
ProdList
28387
Advantage
80
TCI Europe
Tel
320-37350700
Fax
+32 (0)37350701
Email
sales@tcieurope.eu
Country
Europe
ProdList
23671
Advantage
75
TCI AMERICA
Tel
800-4238616
Fax
+1-888-520-1075 / +1-503-283-1987
Email
sales@tciamerica.com
Country
Americas
ProdList
23653
Advantage
75
Shanghai Aladdin Bio-Chem Technology Co.,LTD
Tel
400-6206333 13167063860
Fax
021-50323701
Email
anhua.mao@aladdin-e.com
Country
China
ProdList
25003
Advantage
65
LETOPHARM LIMITED
Tel
+86-21-5821 5861
Fax
+86-21-5106 2861
Email
sales@letopharm.com
Country
China
ProdList
2384
Advantage
58
Shanghai Lollane Biological Technology Co.,Ltd.
Tel
021-52996696,15000506266 15000506266
Fax
+86-21-52996696
Country
China
ProdList
4757
Advantage
55
More
Less

View Lastest Price from 2-ButynaMide, N-[4-[(3-broMophenyl)aMino]-6-quinazolinyl]- manufacturers

Career Henan Chemical Co
Product
N-[4-(3-bromoanilino)quinazolin-6-yl]but-2-ynamide 194423-06-8
Price
US $1.00/KG
Min. Order
1KG
Purity
Min98% HPLC
Supply Ability
g/kg/ton
Release date
2019-12-23

194423-06-8, 2-ButynaMide, N-[4-[(3-broMophenyl)aMino]-6-quinazolinyl]-Related Search:


  • CL-387785 (EKI-785)
  • N-(4-(3-bromophenylamino)quinazolin-6-yl)but-2-ynamide
  • N-[4-[(3-broMophenyl)aMino]-6-quinazolinyl]-2-ButynaMide CL-387785
  • 2-ButynaMide, N-[4-[(3-broMophenyl)aMino]-6-quinazolinyl]-
  • CL-387785, >=98%
  • 785
  • EKI-785; WAY-EKI 785; CL387785; CL 387785; EKI785; WAY-EKI785; EKI 785;CL-387;785
  • CS-1630
  • CL-38875
  • EKB 785
  • WAY-EKI 785
  • EKI-785 CL-38875
  • CL-387
  • N-[4-(3-bromoanilino)quinazolin-6-yl]but-2-ynamide
  • -387785
  • 2-ButynaMide, N-[4-[(3-broMophenyl)aMino]-6-quinazolinyl]- USP/EP/BP
  • CL-387785,ErbB-1,HER1,CL387785,EGFR,EKI785,inhibit,Inhibitor,CL 387785,EKI 785,Epidermal growth factor receptor
  • CL-387785, 10 mM in DMSO
  • CL-387785 (EKI-785) ,S7557
  • 194423-06-8
  • Inhibitors